Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$8.20 USD
-0.79 (-8.79%)
Updated Jun 7, 2024 03:51 PM ET
After-Market: $8.79 +0.59 (7.20%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Brokerage Reports
Oncternal Therapeutics, Inc. [ONCT]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dose Escalation Continues for ONCT-534; Modulating PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ONCT-808 Initial Efficacy; Safety Concerns Amend Protocol; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial ONCT-808 Results Expected by YE; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Including ONCT-808 in Our Forecasts; Upgrading to Buy and $2 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial ONCT-808 Data by End-2023; 2Q23 Financials; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Competitive Landscape Updates From ASCO Conference; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Zilovertamab Development Discontinued; Downgrading to Neutral Without Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ROR1-Targeted CAR-T Data by Year-End; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Authorization Application Submitted for ONCT-808; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Financials Reported; Modulating PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Preclinical Results for ROR1-Targeted CAR-T Presented at EHA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated Zilovertamab Results Presented at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Updated Zilovertamab Results Slated for ASCO; 1Q22 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Zilovertamab Acceleration; ONCT-216 Deprioritized; 4Q21 Results; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Zilovertamab + Imbruvica MCL Phase 3 Trial Design Finalized; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASH Takeaways; Zilovertamab Continues to Shine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Oncternal Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Zilovertamab Combo Beats Historical Controls; 3Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R